Fennec Pharmaceuticals Inc.
Income Statement
| Line Item | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $472.0K | $256.0K | $357.0K | $579.0K | $2.1M | $1.5M |
| SG&A Expense | $2.4M | $1.6M | $2.5M | $1.3M | $1.5M | $1.9M |
| Operating Income | $-2.9M | $-1.9M | $-2.9M | $-1.9M | $-3.6M | $-3.4M |
| Operating Margin | — | — | — | — | — | — |
| Interest Expense | — | — | — | $0 | $0 | $0 |
| Pretax Income | $-2.8M | $-658.0K | $-2.2M | $1.8M | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | — |
| Net Income | $-2.8M | $-659.0K | $-2.2M | $1.8M | $-5.2M | $4.7M |
| Net Margin | — | — | — | — | — | — |
| EPS (Basic) | $-0.22 | $-0.06 | $-0.22 | $0.19 | $-0.21 | $0.20 |
| EPS (Diluted) | $-0.22 | $-0.06 | $-0.22 | $0.17 | $-0.21 | $0.19 |
| Shares Outstanding (Basic) | 12.8M | 10.8M | 9.9M | 9.7M | 25.2M | 24.0M |
| Shares Outstanding (Diluted) | 12.8M | 10.8M | 9.9M | 10.6M | 25.2M | 24.1M |
| Dividends Per Share | — | — | — | — | — | — |